BMS buys Orum’s drug programme combining ADC, protein degradation
06 Nov 2023
ADCPhase 1
Bristol Myers Squibb acquired Orum Therapeutics’ anti-CD33 antibody-enabled GSPT1 degrader ORM-6151 under a deal potentially worth $180 million, including an upfront payment of $100 million. Orum noted Monday that the experimental drug has received FDA clearance for a Phase I study in patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndromes.
Preclinical data presented last year showed that in CD33-expressing cell lines and primary relapsed/refractory AML patient blasts, ORM-6151 had picomolar potency and efficacy superior to clinically equivalent doses of compounds including Pfizer’s antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin). The findings also indicated that ORM-6151 had activity in Mylotarg-resistant cell lines.
Orum CEO Sung Joo Lee suggested that the deal with Bristol Myers Squibb validates the company’s dual-precision targeted protein degradation (TPD²) approach, which aims “to improve the therapeutic window and realise the full potential of targeted protein degraders through precision delivery to cancer cells via antibody-drug conjugates.”
Along with the upfront payment, Orum is eligible to receive milestone payments from Bristol Myers Squibb, although further details were not disclosed.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.